Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 1
1997 3
1998 1
1999 2
2000 4
2001 3
2003 1
2005 1
2006 1
2007 2
2008 2
2009 4
2010 2
2012 2
2013 4
2014 3
2015 1
2016 2
2017 3
2018 1
2019 1
2022 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.
Cheminant M, Lhermitte L, Bruneau J, Sicard H, Bonnafous C, Touzart A, Bourbon E, Ortonne N, Genestier L, Gaulard P, Palmic P, Suarez F, Frenzel L, Naveau L, Bazarbachi A, Dussiot M, Waast L, Avettand-Fenoel V, Brouzes C, Pique C, Lepelletier Y, Asnafi V, Marçais A, Hermine O. Cheminant M, et al. Among authors: sicard h. Blood. 2022 Sep 29;140(13):1522-1532. doi: 10.1182/blood.2022016765. Blood. 2022. PMID: 35687761 Clinical Trial.
Structure and functions of nucleolin.
Ginisty H, Sicard H, Roger B, Bouvet P. Ginisty H, et al. Among authors: sicard h. J Cell Sci. 1999 Mar;112 ( Pt 6):761-72. doi: 10.1242/jcs.112.6.761. J Cell Sci. 1999. PMID: 10036227 Review.
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. Fournié JJ, et al. Among authors: sicard h. Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub 2012 Dec 17. Cell Mol Immunol. 2013. PMID: 23241899 Free PMC article. Review.
KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.
Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. Hurabielle C, et al. Among authors: sicard h. Br J Dermatol. 2018 Jul;179(1):197-199. doi: 10.1111/bjd.16322. Epub 2018 May 9. Br J Dermatol. 2018. PMID: 29315492 No abstract available.
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. Decroos A, et al. Among authors: sicard h. Haematologica. 2023 May 11. doi: 10.3324/haematol.2022.282220. Online ahead of print. Haematologica. 2023. PMID: 37165836 Free article.
The PPARα pathway in Vγ9Vδ2 T cell anergy.
Poupot M, Boissard F, Betous D, Bardouillet L, Fruchon S, L'Faqihi-Olive F, Pont F, Mekaouche M, Ingoure S, Sicard H, Dubreuilh G, Fournié JJ. Poupot M, et al. Among authors: sicard h. Cell Mol Biol Lett. 2014 Dec;19(4):649-58. doi: 10.2478/s11658-014-0218-0. Epub 2014 Nov 25. Cell Mol Biol Lett. 2014. PMID: 25424910 Free PMC article.
43 results